CORT

Corcept Therapeutics Inc. (CORT) | Rumor.io

Corcept Therapeutics

CORT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,124

Bullish sentiment (50-day avg)99%

Price to earnings ratio258

Market capitalization12.5B

Earnings per share0.45

Dividend yield (TTM)—

Revenue (annual)761.4M

Net income (annual)99.7M

Social

What share of all stock conversation is about CORT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 30

Corcept Therapeutics' stock has risen 226% since President Donald Trump's purchase of the company's shares, and has surged 30% today following the FDA's approval of its drug Lifyorli.
The company's stock has gone from $30 to $113 in a few months, with all three major catalysts breaking in its favor, leading to an amazing run for investors.
Corcept's drug Lifyorli has achieved significant results, including a 87% reduction in the risk of death for patients treated with the 300 mg dose of dazucorilant, a treatment for amyotrophic lateral sclerosis (ALS).

Generated by AI

Sentiment

Of the messages about CORT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0% -100	77.78% -21.67	72.41% +39.2
Bearish	100%	100% new	22.22% +21.67	27.59% -39.2

Bullish· Mar 25

Corcept Therapeutics Incorporated's ($CORT) drug Relacorilant for platinum-resistant ovarian cancer has been approved by the FDA, positioning it as a potential new standard of care.
The company's Korlym revenue will remain strong, and its expansion into oncology opens up a massive total addressable market (TAM).
Corcept Therapeutics Incorporated's ($CORT) stock price is expected to resume upward momentum, with a target price of $110, and could reach $200 or more in the long term.

Bearish· Feb 19

The patent ruling against Corcept Therapeutics has led to a decline in the company's stock price, with some analysts attributing the move to the unfavorable ruling.
The introduction of a generic competitor to Corcept's flagship drug, Recorlev, is expected to put significant pressure on the company's revenue and margins, with some estimates suggesting that the generic could capture 50%+ of the market share at 60-80% discounts to the original branded pricing.
Corcept's reliance on its flagship drug, Korlym, has made the company vulnerable to the decline of this revenue stream, with some analysts suggesting that the company's revenue could decline to $400-500M within 18-24 months as generics capture a significant share of the market.

Generated by AI

Topics

Of the messages about CORT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	94.87%	31.19%
Technical Analysis	—	—	2.56%	5.81%
Analysts	—	—	2.56%	15.03%
Controversies	—	—	0%	23.8%
Earnings	—	—	0%	2.48%
Macro	—	—	0%	21.69%

Earnings· Nov 1

$CORT beats Estimize EPS consensus by 1c, misses revenue consensus by $3.84M.
Reports FQ3 earnings of 22c EPS and $64.45M revenue.
Beats Estimize EPS consensus by 1c, misses revenue consensus by $3.84M.

Announcements· Jan 22

Corcept Therapeutics' pivotal Phase 3 ROSELLA trial of relacorilant in patients with platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in the risk of death.
The trial's success indicates a potential new treatment option for patients with platinum-resistant ovarian cancer, with relacorilant demonstrating a significant improvement in overall survival.
The FDA is expected to make a decision on the approval of relacorilant in July 2026, with some analysts predicting that the treatment could do $5 billion in annual sales.

Controversies· Feb 19

Corcept Therapeutics' (CORT) shares fell sharply after a Federal Circuit ruling affirmed no patent infringement by Teva's generic version of Korlym.
The ruling does not invalidate any patents, shorten exclusivity, or approve a generic launch, but it does cover a specific scenario where Korlym is used with strong CYP3A inhibitors, affecting a small minority of prescriptions.
The decision is mildly negative for CORT, but not thesis-breaking, and the company remains profitable and cash-generating, with its core Korlym franchise unaffected.

Technical Analysis· Dec 31

The author is watching CORT for a potential breakout or breakdown on the daily chart, with high relative volume and institutional interest.
The stock has capitulated, but the author believes it's oversold and due for a rebound, citing algo support, value disconnect, and gap fill as reasons for a potential reversal.
The author is looking for CORT to complete a 50% move down and then bounce back, with a target of $40 or $42 by next week, and is considering a long position with a stop at $33.00 and a target at $40.00.

Generated by AI

Community

Of the messages about CORT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90.24%	27.49%	21.36%
Newcomers	0%	9.76%	72.51%	78.64%

Regulars· Jul 30

Corcept Therapeutics' stock has experienced a significant increase in value, rising from $30 to $113 in a few months, with all three major catalysts breaking in its favor.
The company's cancer drug Lifyorli has had a successful launch, with $47.6 million in sales in the first quarter, placing it among the top cancer drug launches of all time.
Analyst H.C. Wainwright has raised its price target on Corcept Therapeutics to $165 from $95, while maintaining a Buy rating, following the company's second-quarter 2026 financial results.

Newcomers· Jul 30

Corcept Therapeutics stock has risen 226% since President Trump's purchase, and it's up another 30% today, valued at $13 billion, up 300% in a year.
The FDA has approved Corcept's drug Lifyorli, and the company is significantly expanding its neuroscience footprint following landmark clinical results for its proprietary selective cortisol modulator, dazucorilant, to treat amyotrophic lateral sclerosis (ALS).
Corcept Therapeutics is profitable, highly profitable for mergers and acquisitions, and has a PDUFA (Premarket Drug User Fee Act) date in December 2026, with significant results treating ALS and future drugs in the pipeline.

Generated by AI

News

Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027

20h agoInvesting.com

Corcept Therapeutics’ oncology president sells $29,842 in stock

2d agoInvesting.com

Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)

4d agoYahoo Finance

Corcept Therapeutics Announces New Endocrinology Division President

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

5d agoThe Globe and Mail

Corcept names Justin Gunn to lead endocrinology division

6d agoInvesting.com

Corcept Announces Planned Leadership Transition

REDWOOD CITY, Calif., September 23, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting Octobe

7d agofinance.yahoo.com

Also Discussed

Investors talking about CORT also mention

#	Name	Attention
1	Vanda Pharmaceuticals Inc.VNDA	0.01%+0.01
2	Crinetics Pharmaceuticals IncCRNX	0%new
3	Supernus Pharmaceuticals, Inc.SUPN	0%new
4	Travere Therapeutics Inc.TVTX	0%0
5	Exelixis Inc.EXEL	0%-0.03
6	Nuvalent, Inc.NUVL	0%0
7	Enanta Pharmaceuticals, Inc.ENTA	0%0
8	Neurocrine Biosciences, Inc.NBIX	0%new
9	Prothena Corp PLCPRTA	0%0
10	Halozyme Therapeutics Inc.HALO	0%0

Corcept Therapeutics Inc.

Healthcare
Biotechnology

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.

Website

Location

101 Redwood Shores Parkway

Redwood City, CA, 94065

United States

Social

What share of all stock conversation is about CORT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 30

Corcept Therapeutics' stock has risen 226% since President Donald Trump's purchase of the company's shares, and has surged 30% today following the FDA's approval of its drug Lifyorli.
The company's stock has gone from $30 to $113 in a few months, with all three major catalysts breaking in its favor, leading to an amazing run for investors.
Corcept's drug Lifyorli has achieved significant results, including a 87% reduction in the risk of death for patients treated with the 300 mg dose of dazucorilant, a treatment for amyotrophic lateral sclerosis (ALS).

Generated by AI

Sentiment

Of the messages about CORT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0% -100	77.78% -21.67	72.41% +39.2
Bearish	100%	100% new	22.22% +21.67	27.59% -39.2

Bullish· Mar 25

Corcept Therapeutics Incorporated's ($CORT) drug Relacorilant for platinum-resistant ovarian cancer has been approved by the FDA, positioning it as a potential new standard of care.
The company's Korlym revenue will remain strong, and its expansion into oncology opens up a massive total addressable market (TAM).
Corcept Therapeutics Incorporated's ($CORT) stock price is expected to resume upward momentum, with a target price of $110, and could reach $200 or more in the long term.

Bearish· Feb 19

The patent ruling against Corcept Therapeutics has led to a decline in the company's stock price, with some analysts attributing the move to the unfavorable ruling.
The introduction of a generic competitor to Corcept's flagship drug, Recorlev, is expected to put significant pressure on the company's revenue and margins, with some estimates suggesting that the generic could capture 50%+ of the market share at 60-80% discounts to the original branded pricing.
Corcept's reliance on its flagship drug, Korlym, has made the company vulnerable to the decline of this revenue stream, with some analysts suggesting that the company's revenue could decline to $400-500M within 18-24 months as generics capture a significant share of the market.

Generated by AI

Topics

Of the messages about CORT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	94.87%	31.19%
Technical Analysis	—	—	2.56%	5.81%
Analysts	—	—	2.56%	15.03%
Controversies	—	—	0%	23.8%
Earnings	—	—	0%	2.48%
Macro	—	—	0%	21.69%

Earnings· Nov 1

$CORT beats Estimize EPS consensus by 1c, misses revenue consensus by $3.84M.
Reports FQ3 earnings of 22c EPS and $64.45M revenue.
Beats Estimize EPS consensus by 1c, misses revenue consensus by $3.84M.

Announcements· Jan 22

Corcept Therapeutics' pivotal Phase 3 ROSELLA trial of relacorilant in patients with platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in the risk of death.
The trial's success indicates a potential new treatment option for patients with platinum-resistant ovarian cancer, with relacorilant demonstrating a significant improvement in overall survival.
The FDA is expected to make a decision on the approval of relacorilant in July 2026, with some analysts predicting that the treatment could do $5 billion in annual sales.

Controversies· Feb 19

Corcept Therapeutics' (CORT) shares fell sharply after a Federal Circuit ruling affirmed no patent infringement by Teva's generic version of Korlym.
The ruling does not invalidate any patents, shorten exclusivity, or approve a generic launch, but it does cover a specific scenario where Korlym is used with strong CYP3A inhibitors, affecting a small minority of prescriptions.
The decision is mildly negative for CORT, but not thesis-breaking, and the company remains profitable and cash-generating, with its core Korlym franchise unaffected.

Technical Analysis· Dec 31

The author is watching CORT for a potential breakout or breakdown on the daily chart, with high relative volume and institutional interest.
The stock has capitulated, but the author believes it's oversold and due for a rebound, citing algo support, value disconnect, and gap fill as reasons for a potential reversal.
The author is looking for CORT to complete a 50% move down and then bounce back, with a target of $40 or $42 by next week, and is considering a long position with a stop at $33.00 and a target at $40.00.

Generated by AI

Community

Of the messages about CORT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90.24%	27.49%	21.36%
Newcomers	0%	9.76%	72.51%	78.64%

Regulars· Jul 30

Corcept Therapeutics' stock has experienced a significant increase in value, rising from $30 to $113 in a few months, with all three major catalysts breaking in its favor.
The company's cancer drug Lifyorli has had a successful launch, with $47.6 million in sales in the first quarter, placing it among the top cancer drug launches of all time.
Analyst H.C. Wainwright has raised its price target on Corcept Therapeutics to $165 from $95, while maintaining a Buy rating, following the company's second-quarter 2026 financial results.

Newcomers· Jul 30

Corcept Therapeutics stock has risen 226% since President Trump's purchase, and it's up another 30% today, valued at $13 billion, up 300% in a year.
The FDA has approved Corcept's drug Lifyorli, and the company is significantly expanding its neuroscience footprint following landmark clinical results for its proprietary selective cortisol modulator, dazucorilant, to treat amyotrophic lateral sclerosis (ALS).
Corcept Therapeutics is profitable, highly profitable for mergers and acquisitions, and has a PDUFA (Premarket Drug User Fee Act) date in December 2026, with significant results treating ALS and future drugs in the pipeline.

Generated by AI

Corcept Therapeutics

Social

Jul 30

Bullish· Mar 25

Bearish· Feb 19

Earnings· Nov 1

Announcements· Jan 22

Controversies· Feb 19

Technical Analysis· Dec 31

Regulars· Jul 30

Newcomers· Jul 30

Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027

Corcept Therapeutics’ oncology president sells $29,842 in stock

Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)

Corcept Therapeutics Announces New Endocrinology Division President

Corcept names Justin Gunn to lead endocrinology division

Corcept Announces Planned Leadership Transition

Also Discussed

Corcept Therapeutics Inc.

Company Information

Location

Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027

Corcept Therapeutics’ oncology president sells $29,842 in stock

Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)

Corcept Therapeutics Announces New Endocrinology Division President

Corcept names Justin Gunn to lead endocrinology division

Corcept Announces Planned Leadership Transition

Also Discussed

Social

Jul 30

Bullish· Mar 25

Bearish· Feb 19

Earnings· Nov 1

Announcements· Jan 22

Controversies· Feb 19

Technical Analysis· Dec 31

Regulars· Jul 30

Newcomers· Jul 30